HOME >> BIOLOGY >> NEWS
Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity

San Diego, CA, 11:00 am EDT, October 22, 2006 OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that ExcaliaTM, a combination of two centrally-acting medications intended to provide and sustain clinically important weight loss, demonstrated significant weight loss in a six month, double-blind, phase IIa clinical study. The magnitude of weight reduction exceeded that seen with placebo. The findings showed that patients completing the blinded 24-week phase lost on average 9.2% of their weight from baseline using Excalia compared to an average of 0.4% weight loss from baseline for patients using placebo. The study results further demonstrate that weight loss continued through an additional 24 week open-label period achieving an average weight loss of 12% from baseline by 48 weeks. These top line phase IIa data for Excalia were presented at the annual meeting of the North American Association for the Study of Obesity (NAASO) in Boston.

"Excalia is designed to achieve an aggressive weight loss trajectory and then to delay the typical weight loss 'plateau' by offsetting one of the body's natural compensatory pathways. These phase II data suggest a level of efficacy that exceeded our expectations in relation to existing approaches," said Gary Tollefson, M.D., Ph.D., OREXIGEN president and CEO. "Excalia is designed to act on a specific reciprocally paired group of hypothalamic neurons that we believe will yield a clinically meaningful weight loss trajectory among significantly overweight individuals. We believe that these positive data support our theoretical approach."

Excalia is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, plus zonisamide, an approved anticonvulsant medication. OREXIGEN's preclinical research suggests that combining these two central nervous system d
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
22-Oct-2006


Page: 1 2 3

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. 1 month post launch, Interactive Autism Network reports 13,000 participants
3. Biosite reports on presentation of preliminary data from sepsis program
4. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
5. Dinosaurs climate shifted too, reports show
6. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
7. Portion distortion may contribute to expanding waistlines, study reports
8. Study reports findings on lung cancer death rates in never smokers
9. Breast implants not associated with cancer risk, study reports
10. Paper reports discovery of virus implicated in genetics of prostate cancer
11. First analysis of FDAs mifepristone adverse event reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2018)... ... November 07, 2018 , ... CallTower, ... announced today a modernized and streamlined White Label Program. This enhancement delivers both ... established reseller administrative control portal. CallTower enhanced their white label program to empower ...
(Date:11/7/2018)... ... 2018 , ... The awards were presented by BioInformatics Inc., ... event was attended by 150 industry executives from leading life science companies that ... winners were determined by responses to an online ballot completed by almost two ...
(Date:11/6/2018)... LINDA, Calif. (PRWEB) , ... November 06, 2018 ... ... about cell characteristics, that subsequently improve disease detection. Advanced systems can perform a ... normal five subclasses of mature white blood cells. They also produce improved flagging ...
Breaking Biology News(10 mins):
(Date:11/9/2018)... ... November 08, 2018 , ... Superior Controls, ... IT solutions with 140 employees on both the east and west coasts, today ... Pennsylvania Convention Center on November 14 and 15 in Philadelphia. The event is ...
(Date:11/5/2018)... ... November 05, 2018 , ... USARAD ... by Siemens Healthineers and several healthcare VC firms announces at Distributed Health 2018 ... a history by purchasing tokens and obtaining its first radiology interpretations, one of ...
(Date:10/31/2018)... CHICAGO (PRWEB) , ... October 30, 2018 , ... ... it will launch operations in Chicago this winter. After its acquisition of the Tally ... tabs, complete transactions and set default tips, Rooam will grow its market share and ...
(Date:10/29/2018)... , ... October 29, 2018 , ... PracticeMatch , ... nationwide, released its schedule of physician career fairs planned for 2019. The company has ... focus hosting live events in the areas of the country which have the highest ...
Breaking Biology Technology:
Cached News: